|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCL19 |
Gene summary for CCL19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCL19 | Gene ID | 6363 |
| Gene name | C-C motif chemokine ligand 19 | |
| Gene Alias | CKb11 | |
| Cytomap | 9p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6IBD6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6363 | CCL19 | P1_S1_AK | Human | Skin | AK | 3.65e-06 | -4.94e-01 | -0.3399 |
| 6363 | CCL19 | P2_S3_AK | Human | Skin | AK | 1.71e-10 | -5.33e-01 | -0.3287 |
| 6363 | CCL19 | P2_S4_SCCIS | Human | Skin | SCCIS | 2.56e-11 | -5.25e-01 | -0.3043 |
| 6363 | CCL19 | P3_S6_AK | Human | Skin | AK | 1.68e-10 | -5.20e-01 | -0.3256 |
| 6363 | CCL19 | P5_S10_cSCC | Human | Skin | cSCC | 2.44e-13 | -5.45e-01 | -0.299 |
| 6363 | CCL19 | P1_cSCC | Human | Skin | cSCC | 2.41e-05 | -5.30e-01 | 0.0292 |
| 6363 | CCL19 | P2_cSCC | Human | Skin | cSCC | 2.02e-08 | -5.05e-01 | -0.024 |
| 6363 | CCL19 | P4_cSCC | Human | Skin | cSCC | 4.03e-04 | -4.09e-01 | -0.00290000000000005 |
| 6363 | CCL19 | P10_cSCC | Human | Skin | cSCC | 6.51e-09 | -5.30e-01 | 0.1017 |
| 6363 | CCL19 | cSCC_p1 | Human | Skin | cSCC | 2.94e-15 | -5.42e-01 | -0.1916 |
| 6363 | CCL19 | cSCC_p10 | Human | Skin | cSCC | 8.39e-12 | -5.41e-01 | -0.2095 |
| 6363 | CCL19 | cSCC_p11 | Human | Skin | cSCC | 4.98e-17 | -5.32e-01 | -0.2102 |
| 6363 | CCL19 | cSCC_p3 | Human | Skin | cSCC | 7.47e-05 | -4.61e-01 | -0.2085 |
| 6363 | CCL19 | cSCC_p4 | Human | Skin | cSCC | 2.63e-09 | -5.23e-01 | -0.2022 |
| 6363 | CCL19 | cSCC_p6 | Human | Skin | cSCC | 7.40e-09 | -4.91e-01 | -0.1989 |
| 6363 | CCL19 | cSCC_p7 | Human | Skin | cSCC | 6.61e-15 | -5.43e-01 | -0.2332 |
| 6363 | CCL19 | cSCC_p8 | Human | Skin | cSCC | 5.31e-12 | -5.15e-01 | -0.1971 |
| 6363 | CCL19 | cSCC_p9 | Human | Skin | cSCC | 2.92e-13 | -5.28e-01 | -0.1991 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000716326 | Skin | AK | establishment or maintenance of cell polarity | 53/1910 | 218/18723 | 1.32e-09 | 1.26e-07 | 53 |
| GO:004578528 | Skin | AK | positive regulation of cell adhesion | 85/1910 | 437/18723 | 3.40e-09 | 2.79e-07 | 85 |
| GO:003009928 | Skin | AK | myeloid cell differentiation | 72/1910 | 381/18723 | 1.76e-07 | 7.28e-06 | 72 |
| GO:003001019 | Skin | AK | establishment of cell polarity | 36/1910 | 143/18723 | 2.24e-07 | 9.02e-06 | 36 |
| GO:004211019 | Skin | AK | T cell activation | 85/1910 | 487/18723 | 5.16e-07 | 1.85e-05 | 85 |
| GO:190165425 | Skin | AK | response to ketone | 43/1910 | 194/18723 | 7.32e-07 | 2.49e-05 | 43 |
| GO:002240725 | Skin | AK | regulation of cell-cell adhesion | 79/1910 | 448/18723 | 8.55e-07 | 2.81e-05 | 79 |
| GO:00509205 | Skin | AK | regulation of chemotaxis | 46/1910 | 223/18723 | 2.56e-06 | 6.91e-05 | 46 |
| GO:005140319 | Skin | AK | stress-activated MAPK cascade | 48/1910 | 239/18723 | 3.43e-06 | 8.82e-05 | 48 |
| GO:003287218 | Skin | AK | regulation of stress-activated MAPK cascade | 41/1910 | 192/18723 | 3.57e-06 | 8.96e-05 | 41 |
| GO:00321038 | Skin | AK | positive regulation of response to external stimulus | 74/1910 | 427/18723 | 3.63e-06 | 9.07e-05 | 74 |
| GO:007030218 | Skin | AK | regulation of stress-activated protein kinase signaling cascade | 41/1910 | 195/18723 | 5.36e-06 | 1.24e-04 | 41 |
| GO:190370625 | Skin | AK | regulation of hemopoiesis | 65/1910 | 367/18723 | 6.74e-06 | 1.52e-04 | 65 |
| GO:003109819 | Skin | AK | stress-activated protein kinase signaling cascade | 48/1910 | 247/18723 | 8.76e-06 | 1.89e-04 | 48 |
| GO:005086317 | Skin | AK | regulation of T cell activation | 59/1910 | 329/18723 | 1.20e-05 | 2.46e-04 | 59 |
| GO:000715919 | Skin | AK | leukocyte cell-cell adhesion | 64/1910 | 371/18723 | 1.87e-05 | 3.52e-04 | 64 |
| GO:000961519 | Skin | AK | response to virus | 63/1910 | 367/18723 | 2.53e-05 | 4.54e-04 | 63 |
| GO:00509217 | Skin | AK | positive regulation of chemotaxis | 31/1910 | 141/18723 | 2.92e-05 | 5.02e-04 | 31 |
| GO:005090015 | Skin | AK | leukocyte migration | 63/1910 | 369/18723 | 3.00e-05 | 5.15e-04 | 63 |
| GO:003134617 | Skin | AK | positive regulation of cell projection organization | 60/1910 | 353/18723 | 5.24e-05 | 8.10e-04 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | GC | ADJ |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | GC | GC |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | HNSCC | Precancer |
| CCL19 | ACKR4 | CCL19_ACKR4 | CCL | HNSCC | Precancer |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Lung | IAC |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Prostate | Tumor |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | ADJ |
| CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | ADJ |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | AK |
| CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | AK |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | cSCC |
| CCL19 | ACKR4 | CCL19_ACKR4 | CCL | Skin | cSCC |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | Healthy |
| CCL19 | CCR7 | CCL19_CCR7 | CCL | Skin | SCCIS |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCL19 | SNV | Missense_Mutation | novel | c.241N>T | p.Arg81Cys | p.R81C | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCL19 | SNV | Missense_Mutation | rs199848815 | c.242N>A | p.Arg81His | p.R81H | Q99731 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CCL19 | SNV | Missense_Mutation | novel | c.91N>A | p.Leu31Met | p.L31M | Q99731 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CCL19 | SNV | Missense_Mutation | novel | c.49N>T | p.Ala17Ser | p.A17S | Q99731 | protein_coding | tolerated(0.2) | benign(0) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| CCL19 | SNV | Missense_Mutation | rs775824329 | c.10C>A | p.Leu4Ile | p.L4I | Q99731 | protein_coding | tolerated_low_confidence(0.06) | benign(0.089) | TCGA-44-8120-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CCL19 | SNV | Missense_Mutation | rs556438266 | c.218N>G | p.Pro73Arg | p.P73R | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-43-2576-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| CCL19 | SNV | Missense_Mutation | rs199848815 | c.242N>A | p.Arg81His | p.R81H | Q99731 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
| CCL19 | SNV | Missense_Mutation | c.127N>A | p.Val43Met | p.V43M | Q99731 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-CD-8536-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | epirubicin | CR |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |